日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

RP1联合Nivolumab治疗晚期抗PD-1治疗失败的黑色素瘤(IGNYTE)

Wong, Michael K; Milhem, Mohammed M; Sacco, Joseph J; Michels, Judith; In, Gino K; Muñoz Couselo, Eva; Schadendorf, Dirk; Beasley, Georgia M; Niu, Jiaxin; Chmielowski, Bartosz; Wise-Draper, Trisha M; Bowles, Tawnya Lynn; Tsai, Katy K; Lebbé, Céleste; Gaudy-Marqueste, Caroline; Middleton, Mark R; Skolariki, Aglaia; Samson, Adel; Chesney, Jason A; VanderWalde, Ari M; Zakharia, Yousef; Harrington, Kevin J; Appleton, Elizabeth; Bommareddy, Praveen K; Zhu, Junhong; Viana, Marcus; Hou, Jeannie W; Coffin, Robert S; Robert, Caroline

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

一项评估 TLR9 激动剂 cavrotolimod 与抗 PD-1 抗体联合治疗晚期实体瘤患者的安全性、有效性和免疫效应的 1b/2 期研究

Milhem, Mohammed M; Wise-Draper, Trisha M; Chandra, Sunandana; Hanna, Glenn J; Laux, Douglas E; Medina, Theresa M; Ansstas, George; Daud, Adil; Kelly, Ciara M; O'Day, Steven J; Perez, Cesar A; Wong, Michael K; Friedlander, Philip A; Kristedja, Timothy S; Burgess, Melissa A; Cowey, C Lance; Hanks, Brent A; Weight, Ryan M; Daniel, Weston L; Feltner, Douglas E; Mix, Scott; Sindelar, Laurel; Bexon, Alice S; Bexon, Martin F; Michel, Robert E; Bhatia, Shailender

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

在程序性死亡受体1阻断耐药的黑色素瘤患者中,瘤内注射维杜托利莫德作为单药治疗或与帕博利珠单抗联合治疗:一项1b期研究的最终分析

Milhem, Mohammed M; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth I; Medina, Theresa; Daud, Adil; Ribas, Antoni; Chmielowski, Bartosz; Niu, Jiaxin; Gibney, Geoffrey T; Margolin, Kim; Olszanski, Anthony J; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Zhao, Luping; Kelley, Heather; Liu, Hong; Kumar, Sujatha; Bobilev, Dmitri; Krieg, Arthur M; Wooldridge, James E; Kirkwood, John M

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

AXL特异性抗体药物偶联物Enapotamab Vedotin治疗晚期实体瘤患者的I/II期研究

Rohrberg, Kristoffer Staal; Lopez, Juanita S; Milhem, Mohammed M; Blank, Christian U; Reijers, Irene; Thistlethwaite, Fiona; Plummer, Ruth; Piha-Paul, Sarina A; Jänne, Pasi A; Shum, Elaine; Shaw, Heather M; Debruyne, Philip R; Lao, Cristopher; Baurain, Jean-Francois; Choe, Jennifer H; Gort, Eelke; Zhao, Yujie; Jerusalem, Guy; Schöffski, Patrick; Chen, Andrew William; Cohen, Eric A; Mankowski, Walter C; Roshkovan, Leonid; Katz, Sharyn I; Kontos, Despina; Brady, Lauren K; Qutaish, Mohammed; Castro, Patricia Garrido; Pencheva, Nora; Bajaj, Gaurav; Fu, Yali; Windfeld, Kristian; Reiter, Panagiota; Jure-Kunkel, Maria; Higgs, Brandon W; Amiri, Katayoun I; Ahmadi, Tahamtan; Forssmann, Ulf; Ramalingam, Suresh S; Vergote, Ignace

PDL1 Expression and Outcomes in Histiocytic Neoplasms

PDL1表达与组织细胞肿瘤预后的关系

Moon, Matthew J; Milhem, Mohammed M; Rieth, John M

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

一项针对转移性肉瘤患者的纳武利尤单抗±伊匹木单抗的多中心、随机、非对照II期研究(Alliance A091401):扩展队列和相关性分析

Seligson, Nathan D; Chen, James L; Goodrich, Austin C; Van Tine, Brian A; Campbell, Jordan D; Richards, Allison L; Antonescu, Cristina R; Liebner, David A; Milhem, Mohammed M; Streicher, Howard; Tap, William D; Schwartz, Gary K; George, Suzanne; D'Angelo, Sandra P

Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma

帕博利珠单抗联合药理剂量抗坏血酸治疗平滑肌肉瘤

Rieth, John M; Belzer, Alex C; Walhof, Mackenzie L; Milhem, Mohammed M

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Olutasidenib (FT-2102)治疗复发或难治性IDH1突变型胶质瘤患者:一项多中心、开放标签的Ib/II期试验

de la Fuente, Macarena I; Colman, Howard; Rosenthal, Mark; Van Tine, Brian A; Levacic, Danijela; Walbert, Tobias; Gan, Hui K; Vieito, Maria; Milhem, Mohammed M; Lipford, Kathryn; Forsyth, Sanjeev; Guichard, Sylvie M; Mikhailov, Yelena; Sedkov, Alexander; Brevard, Julie; Kelly, Patrick F; Mohamed, Hesham; Monga, Varun

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Talimogene laherparepvec联合ipilimumab对比ipilimumab单药治疗晚期黑色素瘤:一项多中心、随机、开放标签II期试验的5年最终分析

Chesney, Jason A; Puzanov, Igor; Collichio, Frances A; Singh, Parminder; Milhem, Mohammed M; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbé, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

中西部肉瘤临床试验合作项目:通过协作方式连接学术界和社区网络,共同应对肉瘤

Heater, Natalie K; Okuno, Scott; Robinson, Steven; Attia, Steven; Seetharam, Mahesh; Siontis, Brittany L; Yoon, Janet; Chawla, Sant; Milhem, Mohammed M; Monga, Varun; Skubitz, Keith; Charlson, John; Hirbe, Angela C; Weiss, Mia C; Van Tine, Brian; Agulnik, Mark